---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010523"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:57:47.222352+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance

## Summary
- Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.
- Net loss $12.4M vs $9.4M loss in Q2 2024; operating expenses $21.2M.
- Added two SPL clients in July (Adicet Bio, Anocca AB); total SPL agreements now 31.
- Updated FY2025: core revenue flat to -10% YoY; SPL Program-related revenue ~$5M.
- Expects year-end cash ≥ $155M; cites customer inventory, reprioritization headwinds.

## SEC filing metadata
- accession: 0001558370-25-010523
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/0001558370-25-010523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/mxct-20250806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010523
- JSON: https://secwatch.observer/filing/0001558370-25-010523.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.